Please login to the form below

Not currently logged in
Email:
Password:

Sun Pharma

This page shows the latest Sun Pharma news and features for those working in and with pharma, biotech and healthcare.

BMS psoriasis drug hits the mark in phase II

BMS psoriasis drug hits the mark in phase II

including Johnson &Johnson’s Stelara (ustekinumab) and follow-up Tremfya (guselkumab), Sun Pharma’s Ilumya (tildrakizumab) and AbbVie’s recently-filed risankizumab.

Latest news

  • Alnylam’s amyloidosis drug heads latest crop of CHMP approvals Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

    The drug was originally developed by India’s Sun Pharma and is licensed to Merck &Co in the US, where it was approved in March. ... Kigabeq (vigabatrin), the other PUMA medicine, has been developed by Orphelia Pharma for infantile spasms (West's

  • Sun Pharma passes milestone with novel psoriasis drug approval Sun Pharma passes milestone with novel psoriasis drug approval

    Ilumya isn’t entirely home-grown, as Sun Pharma licensed the interleukin-23 (IL-23) inhibitor for Merck &Co/MSD in 2014, but the green light is a landmark along the ... With the approval of Ilumya and our long-standing commitment in dermatology, we are

  • Janssen files Stelara follow-up guselkumab in Europe Janssen files Stelara follow-up guselkumab in Europe

    pharma Joaquin Duato is a potential $1bn product that will "provide a significant boost to our leadership in psoriasis". ... AZ) MEDI2070 candidate, tildrakizumab from Sun Pharma (formerly MSD) and Boehringer Ingelheim/AbbVie's BI 655066, all of which

  • AZ licenses inflammatory bowel disease drug to Allergan for $1.52bn AZ licenses inflammatory bowel disease drug to Allergan for $1.52bn

    Other selective IL-23 blockers coming through the pipeline include Janssen's guselkumab, tildrakizumab from Sun Pharma (formerly MSD) and Boehringer Ingelheim/ AbbVie's BI 655066. ... In the last few weeks alone it has agreed a $1.7bn deal to acquire

  • Explosive evolution Explosive evolution

    For example, Roche, Sun Pharma and Fresenius each succeed by virtue of excellent new product development, supply chain management and customer relationship management respectively. ... You must direct your own evolution. The increasing diversity and

More from news
Approximately 6 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • Deal Watch December 2016 Deal Watch December 2016

    295. Novartis (Switzerland). Sun Pharma (India). Asset acquisition. Odomzo (sonidegib; hedgehog pathway inhibitor), approved in basal cell carcinoma. ... Sun Pharma. 3.5%. BSN Medical. Svenska Cellulosa. -0.7%. Claris. Baxter. -1.3%.

  • Deal Watch November 2016 Deal Watch November 2016

    Sun Pharma will also assume Biosintez's $36m debt as part of this transaction. ... acquisition - company. 78. JSC Biosintez/ Sun Pharma. Russian pharma focusing on hospital segment with 2015 revenues of approx $52m.

  • Choosing destiny Choosing destiny

    to, for example, Sun Pharma and vice-versa.

  • Deal Watch July 2016 Deal Watch July 2016

    In at numbers 2, 3 and 4 are the LEO-AstraZeneca deal with an upfront of $115m, Astellas-Cytokinetics at $95m and Almirall-Sun Pharma at $50m (see below). ... Almirall paid $50m upfront to Sun Pharma for a licence to tildrakizumab (an IL-23p19 antibody)

  • Pharma deals during April 2014 Pharma deals during April 2014

    may not be as simple as it seems. Last year the FDA imposed export bans from 20 or so plants in India and warned several others, and whilst Sun Pharma has ... is rumoured that a solution will be to replace the Ranbaxy brand with the Sun Pharma moniker

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Health editor at The Sun newspaper joins Ruder Finn Health editor at The Sun newspaper joins Ruder Finn

    Emma Morton appointed media strategist at PR firm. Emma Morton, health and science editor at UK newspaper The Sun,  is to join the London healthcare team of communications firm Ruder Fin ... Morton spent 13 years at The Sun, initially joining as a

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • How To Become an MSL – Online Training

    Michael Milane, MD, MBA DUSA Pharmaceuticals, a SUN Pharma company . Executive Director of Medical Affairs Jennifer Williams, PhD, JD, MBA, MS, RN Bard Medical Director of Medical Science Liaisons.

  • Cogora

    Nutricia. Orion Pharma. Orphan Europe. Pfizer. Portola. Prostate Cancer UK. Primary Care Respiratory Society. ... Reckitt Benckiser. Stallergenes. Sun Pharma. Takeda. ThermoFisher Scientific. Vertex.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics